Accession Number : ADA524529


Title :   Therapy of Prostate Cancer Using a Human Antibody Targeting the Type 1 Insulin-Like Growth Factor Receptor (IGF-IR)


Descriptive Note : Final rept. 30 Nov 2004-29 Aug 2009


Corporate Author : WASHINGTON UNIV SEATTLE OFFICE OF SPONSORED PROGRAMS


Personal Author(s) : Plymate, Stephen R


Full Text : https://apps.dtic.mil/dtic/tr/fulltext/u2/a524529.pdf


Report Date : Sep 2009


Pagination or Media Count : 72


Abstract : During this funding period we have shown that inhibition of the type 1 IGF receptor with a fully human monoclonal antibody can delay prostate cancer growth in intact and castrate human xenograft mouse models. Further IGF-IR inhibition of IGF-IR greatly enhanced the effects of castration and docetaxel on prostate cancer. There was a significant effect on prostate cancer when growing in bone, especially in combination with Docetaxel. There was no evidence of significant treatment toxicity. The results of these preclinical studies have led to phase 1 and 2 clinical trials in each instance.


Descriptors :   *PROSTATE CANCER , GROWTH(GENERAL) , CLINICAL MEDICINE , THERAPY , MONOCLONAL ANTIBODIES , INHIBITION , PROSTATE GLAND , TOXICITY , TARGETING


Subject Categories : Anatomy and Physiology
      Medicine and Medical Research


Distribution Statement : APPROVED FOR PUBLIC RELEASE